What are Orgenesis Inc's Business Segments?
Orgenesis Inc is a biotechnology company that specializes in developing cellular therapies for the treatment of various diseases. The company operates through several segments, including Contract Development and Manufacturing Organization (CDMO), Point-of-Care Cell Therapy, and Immune Cell Therapy.
The CDMO segment of Orgenesis Inc offers contract research and development services to various biotechnology companies. This segment provides expertise in the development of cellular therapies, including CAR-T cells, gene therapies, and stem cells.
The Point-of-Care Cell Therapy segment of Orgenesis Inc offers a platform for patients to receive personalized cellular therapies in a clinical setting. The company uses its proprietary technology, including its Point-of-Care Device and CellGROW bioreactor system, to produce these therapies on-site.
The Immune Cell Therapy segment of Orgenesis Inc focuses on developing immunotherapies that can treat cancer and autoimmune diseases. This segment uses CAR-T cells and other cellular therapies to target specific cells in the body and activate the immune system to fight the disease.
Orgenesis Inc offers various products and services, including:
1. CellGROW bioreactor system: This is a patented technology that produces large numbers of cells for use in cellular therapies. The system can be used in both research and clinical settings.
2. Point-of-Care Device: This technology enables the production of cellular therapies on-site, providing patients with a personalized treatment plan.
3. Immune cell therapy products: Orgenesis offers CAR-T cells and other immunotherapies for the treatment of cancer and autoimmune diseases.
4. Contract research and development services: The CDMO segment of the company offers contract research and development services to various biotechnology companies.
Overall, Orgenesis Inc is a biotechnology company that offers a comprehensive range of products and services for the development and production of cellular therapies for a wide range of diseases. The company's focus on personalized medicine and point-of-care therapies makes it a unique player in the biotechnology industry.
|